Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Aroa Biosurgery Ltd ( (AU:ARX) ) has issued an announcement.
Aroa Biosurgery Limited is set to conduct a webinar featuring CEO Brian Ward and CFO James Agnew on January 29th to discuss the company’s December Quarterly Results. The event will also include a discussion on a recent clinical study regarding limb salvage using their innovative soft tissue reconstruction technology. This initiative reflects Aroa’s ongoing commitment to transparency with investors and stakeholders while showcasing their advancements in regenerative medicine.
More about Aroa Biosurgery Ltd
Aroa Biosurgery is a company specializing in soft-tissue regeneration, focusing on developing, manufacturing, and distributing medical and surgical products to aid in the healing of complex wounds and soft tissue reconstruction. Utilizing their proprietary AROA ECM™ technology platform, derived from ovine forestomach biomaterial, the company has seen over 7 million of their products used globally. Aroa Biosurgery is headquartered in Auckland, New Zealand, and is listed on the Australian Securities Exchange, with a significant market presence in the United States through direct sales and partnerships.
YTD Price Performance: -3.90%
Average Trading Volume: 364,951
Technical Sentiment Consensus Rating: Sell
Current Market Cap: A$255.2M
For a thorough assessment of ARX stock, go to TipRanks’ Stock Analysis page.
